What this trial means for you
This study is by invitation only — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying GLP-1, Placebo for longevity, quality of life, mood.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * New or existing AgelessRx patient * Adults (aged 18-65) * Any sex * Any ethnicity * BMI ≥ 20 kg/m\^2 * Interest in taking microdoses of semaglutide for health and longevity improvement with no intent to seek weight loss improvement. Exclusion Criteria: * Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s) * History of bariatric surgery * Use of other weight-loss medications currently or within the past 6 months * Contraindications to semaglutide * Significant psychiatric illness that may affect participation * Pregnant or breastfeeding individuals
Study sites by state
Michigan
- AgelessRx — Ann Arbor
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)